Difference between revisions of "Avelumab (Bavencio)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Immunotherapy" to "Category:Immunotherapeutic") |
m |
||
| Line 9: | Line 9: | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
*[[Merkel cell carcinoma]] | *[[Merkel cell carcinoma]] | ||
| + | *[[Renal cell carcinoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 14: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | + | ===[[Bladder cancer]]=== | |
| − | *5/9/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm557162.htm | + | *5/9/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm557162.htm Granted accelerated approval] for patients with locally advanced or metastatic [[bladder cancer|urothelial carcinoma]] whose disease progressed during or following [[:Category:Platinum_agents|platinum-containing chemotherapy]] or within 12 months of neoadjuvant or adjuvant [[:Category:Platinum_agents|platinum-containing chemotherapy]]. ''(New disease entity)'' |
| + | |||
| + | ===[[Merkel cell carcinoma]]=== | ||
| + | *3/23/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm547965.htm Approved] for the treatment of patients 12 years and older with metastatic [[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]. ''(Initial approval)'' | ||
| + | |||
| + | ===[[Renal cell carcinoma]]=== | ||
| + | *5/14/2019: Approved in combination with [[Axitinib (Inlyta)|axitinib]] for first-line treatment of patients with advanced [[Renal cell carcinoma|renal cell carcinoma (RCC)]]. ''(New disease entity)'' | ||
==Also known as== | ==Also known as== | ||
| Line 34: | Line 41: | ||
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
[[Category:Merkel cell carcinoma medications]] | [[Category:Merkel cell carcinoma medications]] | ||
| + | [[Category:Renal cell carcinoma medications]] | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
Revision as of 02:11, 17 May 2019
General information
Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Avelumab binds to PD-1 and B7.1 receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, avelumab stimulates immune responses, including anti-tumor immune effects.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
Bladder cancer
- 5/9/2017: Granted accelerated approval for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. (New disease entity)
Merkel cell carcinoma
- 3/23/2017: Approved for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma (MCC). (Initial approval)
Renal cell carcinoma
- 5/14/2019: Approved in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC). (New disease entity)
Also known as
- Code name: MSB0010718C
- Brand name: Bavencio